[1] RAZUMILAVA N,GORES G J.Cholangiocarcinoma[J].Lancet,2014,383(9935):2168-2179.
[2] KHAN S A,DAVIDSON B R,GOLDIN R D,et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma:an update[J].Gut,2012,61(12):1657-1669.
[3] DODSON R M,WEISS M J,COSGROVE D,et al.Intrahepatic cholangiocarcinoma:management options and emerging therapies[J].J Am Coll Surg,2013,217(4):736-750.
[4] BLECHACZ B,GORES G J.Cholangiocarcinoma:advances in pathogenesis,diagnosis,and treatment[J].Hepatology,2008,48(1):308-321.
[5] KHAN S A,EMADOSSADATY S,LADEP N G,et al.Rising trends in cholangiocarcinoma:is the ICD classification system misleading us?[J].J Hepatol,2012,56(4):848-854.
[6] RIZVI S,GORES G J.Pathogenesis, diagnosis, and management of cholangiocarcinoma[J].Gastroenterology,2013,145(6):1215-1229.
[7] SPOLVERATO G,KIM Y,ALEXANDRESCU S,et al.Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J].Ann Surg Oncol,2016,23(1):235-243.
[8] PARK J,KIM M H,KIM K P,et al.Natural history and prognostic factors of advanced cholangiocarcinoma without surgery,chemotherapy,or radiotherapy:a large-scale observational study[J].Gut Liver,2009,3(4):298-305.
[9] LEE J,PARK S H,CHANG H M,et al.Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer:a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncology,2012,13(2):181-188.
[10] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[11] U.S.Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 November 27,2017 National Institutes of Health National[C/OL].https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Conversion_Amendment_Request.pdf
[12] AMINI N,EJAZ A,SPOLVERATO G,et al.Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States:a population-based analysis[J].J Surg Oncol,2014,110(2):163-170.
[13] 许健,曹建民,卢光明.氩氦刀靶向消融治疗实体肿瘤的评价[J].介入放射学杂志,2009,18(7):481-483.
[14] YU M A,LIANG P,YU X L,et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma[J].Eur J Radiol,2011,80(2):548-552.
[15] ZHANG S J,HU P,WANG N,et al.Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma[J].Ann Surg Oncol,2013,20(11):3596-3602.
[16] AMINI A,GAMBLIN T C.Palliation:treating patients with inoperable biliary tract and primary liver tumors[J].Surg Oncol Clin N Am,2014,23(2):383-397.
[17] 王延明,王能,许赟,等.微波消融治疗7403例肝癌的严重并发症[J].中华肝胆外科杂志,2016,22(10):655-660.
[18] 张德东,于晓玲,梁萍,等.经皮微波消融治疗肝内胆管细胞癌的疗效分析[J/OL].中华医学超声杂志(电子版),2011,8(11):2314-2319.
[19] CHIANG J,CRISTESCU M,LEE M H,et al.Effects of microwave ablation on arterial and venous vasculature after treatment of hepatocellular carcinoma[J].Radiology,2016,281(2):617.
[20] MORELAND A J,LUBNER M G,ZIEMLEWICZ T J,et al.Evaluation of a thermoprotective Gel for hydrodissection during percutaneous microwave ablation:in vivo results[J].Cardiovasc Intervent Radiol,2015,38(3):1-9.
[21] 陈敏山,陈敏华,叶胜龙,等.原发性肝癌局部消融治疗的专家共识[J].临床肿瘤学杂志,2011,16(1):70-73.
[22] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华消化外科杂志,2017,16(7):705-720.
[23] 朱传东,王礼学,徐瀚峰,等.CT引导下经皮微波消融术治疗特殊部位小肝癌36例临床研究[J].现代医学,2017,36(11):1568-1572. |